NHS England has unveiled a ‘medicines reset’ initiative to optimise treatment use, significantly increase savings, and accelerate access to new therapies through innovative schemes and strategic programmes supported by expert collaborations and government deals.
NHS England is advancing a “medicines reset” initiative aimed at maximising the benefits of prescribed medicines for patients and taxpayers alike. The programme, backed by experts from the University of York and the Department of Health and Social Care, seeks to optimise the use of existing treatments to improve health outcomes more effectively. The scheme underscores the potential to go beyond current practices with adequate funding, ensuring that patients derive greater value from their medicines and that public funds are used more efficiently.
This initiative comes amid broader efforts to enhance the affordability and accessibility of medicines within the NHS. A cornerstone of these efforts is the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), a landmark deal involving the UK government, NHS England, and the pharmaceutical industry. This agreement is forecast to save the NHS £14 billion over five years by capping the growth in branded medicine sales while simultaneously unlocking improved patient access to innovative treatments. The scheme also aims to bolster the UK’s life sciences sector by supporting investment in clinical trials and pharmaceutical manufacturing domestically.
In recent years, the NHS has demonstrated considerable success in negotiating better medicines prices, notably saving £1.2 billion over three years. Much of these savings stem from bulk procurement of generic alternatives, exemplified by the cost-effective sourcing of adalimumab, a widely used medication. Such strategies enable the NHS to sustain high-quality care while controlling expenditure, reflecting a broader commitment to financial sustainability balanced with patient-centric service improvements.
Moreover, NHS efforts extend to ensuring patients correctly adhere to their new medications. Initiatives such as the New Medicine Service (NMS) pharmacy scheme have proven valuable, with NIHR-funded research attributing £558 million in NHS savings to improved patient adherence and consequent reductions in avoidable hospital admissions. This scheme supports patients starting long-term treatments, highlighting the NHS’s focus on not just accessing medicines but also optimising their real-world use and outcomes.
Additionally, NHS England runs a Medicines Repurposing Programme, which explores innovative uses of existing licensed medicines that fall outside their initial marketing authorisations. This tailored approach seeks to enhance clinical results, patient experience, and value for money by unlocking new therapeutic potentials without necessarily developing entirely new drugs.
Complementing these initiatives is a government-established pathway ensuring timely introduction and funding of new medicines in the NHS. This pathway includes managed access arrangements to collect real-world evidence on drug effectiveness and mandates NHS commissioners to fund medicines recommended by NICE evaluations within a three-month window, reinforcing rapid patient access to new therapies.
Collectively, these strategies illustrate a comprehensive NHS approach to managing medicines—from cost containment and service innovation to patient adherence and clinical optimisation—positioning the health service to better serve the population’s needs within constrained budgets.
📌 Reference Map:
- Paragraph 1 – [1], [6]
- Paragraph 2 – [2], [3]
- Paragraph 3 – [4]
- Paragraph 4 – [5]
- Paragraph 5 – [6]
- Paragraph 6 – [7]
Source: Noah Wire Services
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
8
Notes:
The narrative presents recent findings from a study by the York Health Economics Consortium at the University of York, commissioned by the National Pharmacy Association (NPA). The earliest known publication date of similar content is 22 August 2025, when the Government announced the shelving of proposals to increase UK spending on medicines by around £1 billion over the next three years. ([standard.co.uk](https://www.standard.co.uk/news/politics/government-proposals-nhs-nice-department-of-health-and-social-care-b1244121.html?utm_source=openai)) The report’s focus on expanding pharmacy services to reduce hospital admissions and save costs is a new development, indicating high freshness. ([standard.co.uk](https://www.standard.co.uk/news/health/nhs-england-university-of-york-experts-department-of-health-and-social-care-b1250765.html?utm_source=openai))
Quotes check
Score:
9
Notes:
Direct quotes from Henry Gregg, chief executive of the NPA, and Nick Hex, leader of the research at York Health Economics Consortium, are included. These quotes appear to be original, with no identical matches found in earlier material. The wording is consistent with their known public statements, suggesting authenticity.
Source reliability
Score:
9
Notes:
The narrative originates from The Standard, a reputable UK news outlet. The report cites a study by the York Health Economics Consortium at the University of York, commissioned by the National Pharmacy Association (NPA), and includes statements from credible figures such as Henry Gregg and Nick Hex. This indicates a high level of reliability.
Plausability check
Score:
8
Notes:
The claims about expanding pharmacy services to reduce hospital admissions and save costs are plausible and align with ongoing discussions about optimising NHS resources. The narrative includes specific figures, such as the potential to save £26.3 million by implementing the discharge medicines service nationwide, and the possibility of 70,000 people avoiding hospitalisation annually. These details are consistent with the study’s findings and are covered by other reputable outlets. ([standard.co.uk](https://www.standard.co.uk/news/health/nhs-england-university-of-york-experts-department-of-health-and-social-care-b1250765.html?utm_source=openai))
Overall assessment
Verdict (FAIL, OPEN, PASS): PASS
Confidence (LOW, MEDIUM, HIGH): HIGH
Summary:
The narrative presents original, recent findings from a credible study commissioned by the NPA and conducted by the University of York. The quotes are authentic, and the information is consistent with other reputable sources, indicating a high level of reliability and plausibility.
